Although the unprecedented long-lasting clinical responses have been achieved with ICBs such as anti-PD-L1 antibody immunotherapy, only a small subset of patients with specific tumor types like melanoma, lung cancer, and colorectal cancer can respond to and obtain therapeutic benefits [1,2,3,4]. This evidence concerns the gene CD274 and lung carcinoma.